Lexicon Pharmaceuticals Inc (LX31)

Currency in EUR
1.00
+0.03(+3.10%)
Closed·
LX31 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.001.00
52 wk Range
0.262.00
Key Statistics
Bid/Ask
0.89 / 0.97
Prev. Close
0.93
Open
1
Day's Range
1-1
52 wk Range
0.26-2
Volume
25.81K
Average Volume (3m)
14.29K
1-Year Change
-37.5%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LX31 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Lexicon Pharmaceuticals Inc Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Compare LX31 to Peers and Sector

Metrics to compare
LX31
Peers
Sector
Relationship
P/E Ratio
0.0x−1.6x−0.5x
PEG Ratio
0.00−0.070.00
Price/Book
0.0x0.8x2.6x
Price / LTM Sales
0.0x41.6x3.3x
Upside (Analyst Target)
0.0%262.2%45.1%
Fair Value Upside
Unlock29.6%7.4%Unlock

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

LX31 Income Statement

People Also Watch

168.10
CRCL
-8.40%
14.8000
QUBT
-0.27%
71.49
OKLO
-6.66%
9.640
ACHR
-3.89%
7.960
NVTS
+8.59%

FAQ

What Stock Exchange Does Lexicon Pharmaceuticals Inc Trade On?

Lexicon Pharmaceuticals Inc is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Lexicon Pharmaceuticals Inc?

The stock symbol for Lexicon Pharmaceuticals Inc is "LX31."

What Is the Lexicon Pharmaceuticals Inc Market Cap?

As of today, Lexicon Pharmaceuticals Inc market cap is 335.44M.

What Is Lexicon Pharmaceuticals Inc's Earnings Per Share (TTM)?

The Lexicon Pharmaceuticals Inc EPS (TTM) is 0.00.

From a Technical Analysis Perspective, Is LX31 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Lexicon Pharmaceuticals Inc Stock Split?

Lexicon Pharmaceuticals Inc has split 0 times.

What is the current trading status of Lexicon Pharmaceuticals Inc (LX31)?

As of 04 Aug 2025, Lexicon Pharmaceuticals Inc (LX31) is trading at a price of 1.00, with a previous close of 0.93. The stock has fluctuated within a day range of 1.00 to 1.00, while its 52-week range spans from 0.26 to 2.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.